4 February 2016 - In response to the opioid abuse epidemic, today Dr. Robert Califf, the FDA’s Deputy Commissioner for Medical Products and Tobacco, along with other FDA leaders, called for a far-reaching action plan to reassess the agency’s approach to opioid medications. The plan will focus on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm484765.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery